Tectonic Therapeutic, Inc.

NASDAQ:TECX

Biotechnology

Healthcare
$21.04 -0.96%

-$0.29 today

Market cap
$411.32M
Beta
1.22
P/E (TTM)
-6.7
EPS (TTM)
-$4.45
52W Low $14.39High $36.03

Volume 0.17M

Average 0.20M

TECX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Tectonic Therapeutic, Inc.NASDAQ: TECX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $20.87M rose 60.1% year over year, behind the +63.7% change in trailing-twelve-month research & development. Sequentially, it rose 27.7% from the prior quarter. Over 3 fiscal years it compounded at +35.3% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +60.1% toward the trailing-twelve-month pace of +63.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.87M+27.7% QoQ
Last fiscal yearDec 2025
$63.49M+53.5% YoY
LTMMar 2026
$71.32M+63.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+60.1%——
1 year+53.5%——
3-year CAGR+35.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
63.49M USD
Year-over-year change
+53.5%
4-year CAGR
+55.1%

Research & Development vs competitors

How TECX compares with its peers on the latest reported figures

  • TECX's LTM Mar 2026 research & development of $71.32M is the lowest of the 4 companies compared; the peer median is $224.7M.
  • Its year-over-year change of +63.7% is the 2nd highest of 4, against a peer median of +56.0%.
  • Over three fiscal years its annual growth of +35.3% compares with a peer median of +83.9%.
TECX Competitors Peer median
Research & Development for TECX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$294.44M +79.9%+83.9%—
GENBGenerate Biomedicines, Inc.FY2025$224.7M +28.2%—704.5%
SEPNSepterna, Inc.LTM Sep 2026$132.66M +56.0%—137.8%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$71.32M +63.7%+35.3%—
Peer median (excluding TECX) $224.7M+56.0%+83.9%421.2%

Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development10.98M25.65M36.97M41.36M63.49M
Selling, General & Admin4.63M7.18M7.68M16.65M20.55M
Operating Expenses15.61M32.83M44.65M58.02M84.04M
Depreciation & Amortization364K1.01M1.48M1.65M1.38M
EBITDA(8.12M)(31.03M)(41.19M)(56.23M)(71.48M)
EBITDA Margin—————
Operating Income(15.61M)(32.83M)(44.65M)(58.02M)(84.04M)
Operating Margin—————
Interest Income0149K581K4.26M11.3M
Interest Expense224K144K152K107K63K
Other Income / Expenses6.68M650K1.83M33K11.12M
Income Before Tax(8.93M)(32.18M)(42.82M)(57.98M)(72.92M)
Pre-Tax Margin—————
Income Tax Expense00001.23M
Net Income(8.93M)(32.18M)(42.82M)(57.98M)(74.15M)
Net Margin—————
EPS (Basic)(33.36)(29.05)(11.59)(3.93)(4.05)
EPS (Diluted)(33.36)(29.05)(11.53)(3.93)(4.05)
Weighted Avg Shares3.57M3.64M3.69M14.77M18.32M
Weighted Avg Shares (Diluted)3.57M3.64M3.71M14.77M18.32M

Tectonic Therapeutic, Inc.

NASDAQ:TECX

Intrinsic Alpha fair value

Locked

Current Price

$21.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.